[go: up one dir, main page]

EA202193351A1 - Связывающая молекула, специфическая в отношении cd73, и применение связывающей молекулы - Google Patents

Связывающая молекула, специфическая в отношении cd73, и применение связывающей молекулы

Info

Publication number
EA202193351A1
EA202193351A1 EA202193351A EA202193351A EA202193351A1 EA 202193351 A1 EA202193351 A1 EA 202193351A1 EA 202193351 A EA202193351 A EA 202193351A EA 202193351 A EA202193351 A EA 202193351A EA 202193351 A1 EA202193351 A1 EA 202193351A1
Authority
EA
Eurasian Patent Office
Prior art keywords
binder
single antibody
antigen
binding portion
specific
Prior art date
Application number
EA202193351A
Other languages
English (en)
Inventor
Цинхао Лю
Вэньлай Чжоу
Хайянь Ян
Хунлин Ван
Original Assignee
Джакобио Фармасьютикалс Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джакобио Фармасьютикалс Ко., Лтд. filed Critical Джакобио Фармасьютикалс Ко., Лтд.
Publication of EA202193351A1 publication Critical patent/EA202193351A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Связывающая молекула, специфическая в отношении CD73, и применение связывающей молекулы. В частности, обеспечиваются отдельное антитело, связывающее CD73 и ингибирующее активность CD73, или антигенсвязывающая часть отдельного антитела, и применение отдельного антитела или его антигенсвязывающей части в лечении заболеваний; также обеспечиваются молекула нуклеиновой кислоты, кодирующая отдельное антитело или его антигенсвязывающую часть, вектор экспрессии для экспрессии отдельного антитела или его антигенсвязывающей части, клетка-хозяин и способ получения.
EA202193351A 2019-06-06 2020-06-05 Связывающая молекула, специфическая в отношении cd73, и применение связывающей молекулы EA202193351A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019090366 2019-06-06
PCT/CN2020/094489 WO2020244606A1 (zh) 2019-06-06 2020-06-05 对cd73具有特异性的结合分子及其用途

Publications (1)

Publication Number Publication Date
EA202193351A1 true EA202193351A1 (ru) 2022-03-21

Family

ID=73653110

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193351A EA202193351A1 (ru) 2019-06-06 2020-06-05 Связывающая молекула, специфическая в отношении cd73, и применение связывающей молекулы

Country Status (12)

Country Link
US (2) US11174319B2 (ru)
EP (1) EP3981790A4 (ru)
JP (1) JP7623706B2 (ru)
KR (1) KR102808557B1 (ru)
CN (1) CN113906051B (ru)
AU (1) AU2020289179B2 (ru)
BR (1) BR112021024553A2 (ru)
CA (1) CA3142640A1 (ru)
EA (1) EA202193351A1 (ru)
MX (1) MX2021014952A (ru)
TW (1) TWI790445B (ru)
WO (1) WO2020244606A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL294437A (en) 2020-01-03 2022-09-01 Incyte Corp Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
US12018089B2 (en) 2020-01-03 2024-06-25 Incyte Corporation Anti-CD73 antibodies and uses thereof
EP4507736A1 (en) 2022-04-13 2025-02-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN116769034B (zh) * 2022-08-12 2024-01-02 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024138910A1 (en) * 2022-12-26 2024-07-04 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Anti-cd73 antibody and use thereof
CN118812710A (zh) * 2023-04-17 2024-10-22 上海鑫湾生物科技有限公司 特异性结合cd73的抗体及其制备方法和应用
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101370830A (zh) * 2005-09-26 2009-02-18 米德列斯公司 抗cd70的人单克隆抗体
RU2717651C2 (ru) * 2014-08-07 2020-03-24 Мемориал Слоан-Кеттеринг Кэнсер Сентер Антитела к церамиду
DK3204417T3 (da) * 2014-10-10 2020-10-12 Innate Pharma Cd73-blokering
EA202090956A3 (ru) * 2014-11-21 2020-12-30 Бристол-Майерс Сквибб Компани Антитела к cd73 и их применения
US11130817B2 (en) * 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
AU2016366548C1 (en) * 2015-12-09 2024-07-25 Bioatla, Llc Humanized anti-CD73 antibodies
NZ753714A (en) * 2017-01-24 2023-03-31 I Mab Biopharma Co Ltd Anti-cd73 antibodies and uses thereof
US20210107989A1 (en) * 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
KR20200021087A (ko) * 2017-06-22 2020-02-27 노파르티스 아게 Cd73에 대한 항체 분자 및 이의 용도

Also Published As

Publication number Publication date
AU2020289179A1 (en) 2021-11-18
KR20220016974A (ko) 2022-02-10
EP3981790A1 (en) 2022-04-13
US20210253730A1 (en) 2021-08-19
KR102808557B1 (ko) 2025-05-14
TW202112814A (zh) 2021-04-01
JP7623706B2 (ja) 2025-01-29
CN113906051A (zh) 2022-01-07
WO2020244606A1 (zh) 2020-12-10
TWI790445B (zh) 2023-01-21
JP2022535840A (ja) 2022-08-10
EP3981790A4 (en) 2023-10-11
CN113906051B (zh) 2025-06-06
CA3142640A1 (en) 2020-12-10
US11174319B2 (en) 2021-11-16
MX2021014952A (es) 2022-04-06
BR112021024553A2 (pt) 2022-05-24
AU2020289179B2 (en) 2024-05-02
US20220064322A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
EA202193351A1 (ru) Связывающая молекула, специфическая в отношении cd73, и применение связывающей молекулы
ZA202100676B (en) Anti-tigit antibody and uses thereof
EA201890796A1 (ru) Новое антитело к мезотелину и содержащая его композиция
EA202092735A1 (ru) Антагонизирующее cd73 антитело
EA201892774A1 (ru) Антитела
CL2016002116A1 (es) Anticuerpos anti-fap y métodos de utilización (divisional sol. n°369-13).
PH12017500918A1 (en) Antibodies against cd73 and uses thereof
EA201890169A1 (ru) Тау-связывающие антитела
NO20083053L (no) Humane monoklonale antistoffer mot O8E
EA201690503A1 (ru) Антитела
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
CN114651013A (zh) 对cd39具有特异性的结合分子及其用途
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
EA201990018A1 (ru) Антитела к с5 и способы их применения
EA201890172A1 (ru) Тау-связывающие антитела
EA201101242A1 (ru) Полностью человеческие антитела, специфические для cadm1
AU2019433019A8 (en) Antibodies binding CD40 and uses thereof
EA201900443A1 (ru) Антитело к pd-l1 и его применение
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
EA201992206A1 (ru) Моноклональное антитело к pd-l1
EA202091569A1 (ru) Моноклональные антитела и способы их применения
ZA202201464B (en) Anti-tigit antibodies and application thereof
EA201300470A1 (ru) Антитела
UA105073C2 (ru) Антитело против фракталкина, композиция и способ лечения воспалительных нарушений
SA519401032B1 (ar) (pd-1) جسم مضاد لموت الخلية المبرمج1 واستخدامه